Close

Yuvraj

Bristol-Myers Squibb announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on...

BRILIQUE (ticagrelor) receives positive opinion from European CHMP for the treatment of Acute Coronary Syndromes

AstraZeneca announced today that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the marketing authorisation application for BRILIQUEâ„¢...

FLUOstar Omega Named Drug Discovery Product of the Year 2010

  BMG LABTECH is proud to announce that the FLUOstar Omega multimode microplate reader has received the award for 'Drug Discovery Product of...

The GRACE study has significant implications for inclusion of women in clinical trials

Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study...

Novartis study shows Onbrez® Breezhaler® is superior to salmeterol in reducing breathlessness for patients with COPD

Results of the Phase III INSIST study show that Onbrez® Breezhaler® (indacaterol) given once-daily is significantly better at improving lung function and reducing breathlessness...

Emisphere Reports Positive Clinical Results for Its Oral Drug Delivery Technology

Emisphere Technologies, Inc. announced that a clinical study found that the company's proprietary oral SNAC (Sodium N- Caprylate ("SNAC") additive, in combination with two...

Emisphere Reports Positive Clinical Results for Its Oral Drug Delivery Technology in Appetite Suppression Study

Emisphere Technologies, Inc. announced that a clinical study found that the company's proprietary oral SNAC (Sodium N- Caprylate ("SNAC") additive, in combination with two...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read